{"preliminary_commentary":{"by_channel":{"x_thread":14,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT00112658\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["FOLFIRINOX"]],"indication":"metastatic pancreatic cancer","name":"PRODIGE 4","nct_id":"NCT00112658","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=prodige-4-nct00112658. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Folfirinox","type":"EXPERIMENTAL"},{"description":null,"label":"Gemcitabine","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2010-06-30","type":"ACTUAL"},"conditions":["Pancreatic Cancer"],"enrollment":{"count":342,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"fluorouracil","otherNames":[],"type":"DRUG"},{"name":"gemcitabine hydrochloride","otherNames":[],"type":"DRUG"},{"name":"irinotecan hydrochloride","otherNames":[],"type":"DRUG"},{"name":"leucovorin calcium","otherNames":[],"type":"DRUG"},{"name":"oxaliplatin","otherNames":[],"type":"DRUG"}],"last_update":"2021-03-08","lead_sponsor":"UNICANCER","official_title":"Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients","overall_status":"COMPLETED","phases":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2010-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective response rate (Phase II)","timeFrame":null},{"measure":"Survival (Phase III)","timeFrame":null}],"references":[{"citation":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C, Bennouna J, Bachet JB, Khemissa-Akouz F, Pere-Verge D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.","pmid":"21561347","type":"RESULT"},{"citation":"Ychou M, Desseigne F, Guimbaud R, et al.: Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): first results of the ACCORD 11 trial. [Abstract] J Clin Oncol 25 (Suppl 18): A-4516, 2007.","pmid":null,"type":"RESULT"},{"citation":"Lambert A, Jarlier M, Gourgou Bourgade S, Conroy T. Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial. PLoS One. 2017 Sep 20;12(9):e0183288. doi: 10.1371/journal.pone.0183288. eCollection 2017.","pmid":"28931010","type":"DERIVED"}],"start_date":{"date":"2004-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer","url":"https://clinicaltrials.gov/study/NCT00112658"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/prodige-4-nct00112658"}